Junshi Biotech (01877) rose more than 6%. As of press release, it rose 6.65% to HK$10.58, with a turnover of HK$8.916 million.
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6%. As of press release, it had risen 6.65% to HK$10.58, with a turnover of HK$8.916 million.
According to the news, Junshi Biotech recently announced that the marketing application for new indications for patients with high-risk unresectable or metastatic renal cell carcinoma in first-line treatment of treprilimab combined with axitinib independently developed by the company was recently approved by the National Drug Administration (NMPA). This is the eighth indication that treprilizumab has been approved in China, and it is also the first approved immunotherapy for kidney cancer in China.
Fangzheng Securities pointed out that the listing of Trepril as an exclusive indication for kidney cancer is expected to drive further sales growth. In 2023, sales revenue of treprilizumab was about 900 million yuan, an increase of about 25% over the previous year. The bank calculated based on the number of new cases of kidney cancer, MPFs, PD-1 penetration rate, and the market share of Trepri. It is estimated that sales of 1L of Trepril to treat renal cell cancer will peak at 457 million yuan. The approval of an exclusive indication for kidney cancer will help further increase its sales.